Novo Nordisk's pricing procedures from the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who's got accused the company of cost gouging, stating the stark distinction among U.S. rates and those in Europe and copyright.In October 2024, Novo Nordisk revealed a review on scientific journal Character about a novel glucose-delicate